Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, with 10% prevalence in patients ! 80 years of age.
Stroke Prevention in Atrial Fibrillation Using Oral Anticoagulants
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, with 10% prevalence in patients ! 80 years of age.
1-3 AF is an independent risk factor for stroke with an annual risk ranging from 2 to 18% based on the presence of other risk factors. Among different oral antithrombotic therapy studied, warfarin was shown to reduce stroke risk by 64% when compared with placebo and by 39% when compared with aspirin in AF patients. 4 Furthermore, it has been shown to be more effective than dual antiplatelets (DAP) when tested as an alternative antithrombotic regimen. 5 Although the effectiveness of warfarin was evident, the safety and complexity of managing warfarin therapy left patients and practitioners searching for alternative treatment options. Since 2010, four direct oral anticoagulants (DOACs) have been introduced into the market as an alternative to warfarin. DOACs act by directly and selectively inhibiting key coagulation factors such as thrombin (i.e., dabigatran) or factor Xa (i.e., rivaroxaban, apixaban, and edoxaban). [6] [7] [8] For many nonvalvular AF patients, DOACs are now recommended as first-line therapy for stroke prevention due to a favorable side effect profile and a lower risk of intracerebral hemorrhage. 9, 10 In addition, these agents do not usually require strict routine monitoring or dose adjustments and have fewer drug-drug and drug-food interactions.
Keywords
► antithrombotic ► antiplatelet ► warfarin ► atrial fibrillation ► acute coronary syndrome
Abstract
Patients with atrial fibrillation (AF) who are treated with oral anticoagulants often have concurrent coronary artery disease. Triple oral antithrombotic therapy (TOAT) is often necessity to prevent stent thrombosis or myocardial infarction associated with percutaneous coronary intervention or acute coronary syndrome in patients with comorbid coronary artery disease and AF. Although the use of TOAT (aspirin, clopidogrel, and warfarin) has excellent efficacy against thrombotic complications, this comes on the expense of increased bleeding risk. This review discusses potential strategies to improve TOAT benefit-risk ratio evidence from the literature. These strategies include: (1) dropping aspirin; (2) reducing the duration of TOAT; (3) switching warfarin to a direct oral anticoagulant (DOAC); (4) the use of DOAC in combination with a single antiplatelet agent; and (5) switching clopidogrel to a novel antiplatelet agent. Although dropping aspirin and reducing TOAT duration should be considered in selected AF patients at low risk of thrombosis, the role of DOACs and novel antiplatelets in TOAT has not been thoroughly studied, and there is limited evidence to support their use currently. Ongoing studies will provide safety and efficacy data to guide clinicians who frequently face the challenge of determining the best TOAT combination for their patients. Although aspirin is known to significantly reduce cardiovascular events after ACS, the addition of clopidogrel as a second antiplatelet was found to improve ACS outcomes significantly compared with aspirin alone. 13, 14 Not long ago, novel antiplatelet agents (prasugrel and ticagrelor) were introduced as alternatives to clopidogrel in the setting of ACS. Prasugrel and ticagrelor generally achieve higher degrees of platelet inhibition than clopidogrel and do not appear to be affected by CYP2C19 polymorphism. 15, 16 As compared with clopidogrel, both agents were shown to improve clinical outcomes among patients with ACS but with an increase in bleeding risk, particularly in those undergoing PCI. 17, 18 Current guidelines recommend the use of DAP for at least 4 weeks after bare-metal stent and for at least 6 months after drug-eluting stent (DES). 19, 20 However, the exact duration of DAP therapy in patients receiving DES placement remains a controversial issue.
Ischemic Risk Prevention in Patients with
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Triple Oral Antithrombotic Therapy
Triple oral antithrombotic therapy (TOAT) is commonly used for patients with AF on oral anticoagulant therapy who experience an ACS or undergo elective PCI. It is estimated that coronary artery disease coexists in 20 to 30% of AF patients who also qualify for oral anticoagulant therapy.
24,25
Aspirin, clopidogrel, and warfarin have long been the mainstay TOAT combination. Despite its adequate efficacy, suboptimal safety remains a topic of much concern, especially given the morbidity and mortality associated with antithromboticrelated bleeding. [26] [27] [28] [29] [30] Potential strategies to improve TOAT (aspirin, clopidogrel, and warfarin) benefit-risk ratio include:
(1) dropping aspirin; (2) reducing the duration of TOAT; (3) switching warfarin to a DOAC; (4) the use of DOAC in combination with a single antiplatelet agent; and (5) switching clopidogrel to a novel antiplatelet agent (►Table 1). In this review, we will discuss evidence from the literature on the efficacy, safety, and usefulness of these different strategies (►Table 2).
Dropping Aspirin
The reported efficacy of the TOAT (aspirin, clopidogrel and warfarin) comes at the expense of increased risk of bleeding. Several observational studies reported two-to threefold increase in bleeding with the use of TOAT when compared with DAP or to the use of warfarin and a single antiplatelet agent. However, as the trial was powered to detect a difference in major bleeding and not in thromboembolic events, there were no statistically significant differences seen between the two study groups for MI, target-vessel revascularization, stroke, or stent thrombosis. All-cause mortality rate was lower in the clopidogrel/warfarin group compared with the TOAT group, which could be mediated by the lower number of bleeding in the clopidogrel/warfarin group. Similar findings were also reported in recently published large datasets highlighting the increased risk of bleeding and lack of clinical benefit associated with TOAT compared with warfarin/single antiplatelet.
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Reducing the Duration of Triple Oral Antithrombotic Therapy
In patients receiving a stent post-ACS/PCI without an indication for oral anticoagulant, shortening the duration of DAP therapy has been studied extensively. These trials yielded mixed results regarding the net clinical efficacy but reached agreement on the increased risk of bleeding with prolonged DAP therapy. 23, 36, 37 Similarly, longer duration of TOAT has long been recognized to increase the risk of bleeding complications. Recently, the ISAR-TRIPLE (Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation) study investigated TOAT after stenting and its duration. 38 Its aim was to evaluate TOAT in AF and Coronary Artery Stenting Elewa et al. 663
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This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 44) in the 6-month group when compared with the 6-week group at 9 months. Individual components of the primary end point were similar, with the exception of a higher incidence of MI in the 6-week compared with the 6-month therapy group (2 vs. 0%; p ¼ 0.03). However, results of this trial should be interpreted in light of several limitations. First, the difference in the incidence of MI is likely due to imbalance in the ischemic events between groups at 6 weeks when both arms were still on TOAT. Only one MI event occurred after 6 weeks (on day 212 post-PCI) while the patient was receiving oral anticoagulation and aspirin. This imbalance is likely due to the early randomization of patients' post-PCI and not at 6 weeks when prior event exposure might have been balanced by randomization.
38
Second, the study was only powered to detect a fairly large reduction (60%) in events, leaving the subgroups underpowered for further analyses. Apart from the ISAR-TRIPLE trial, shortening the duration of clopidogrel in TOAT-treated patients has not been studied prospectively. A retrospective nationwide registry found no clinical benefit and possible harm with the prolonged use of TOAT beyond 4 months.
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Switching Warfarin to a Direct Oral Anticoagulant
DOACs have repeatedly reduced the risk of intracerebral bleeding when compared with warfarin in several phase III studies. 39 Therefore, replacement of warfarin with a DOAC in TOAT is a logical strategy to reduce the risk of bleeding in patients requiring combined anticoagulant and antiplatelet therapy. Unlike warfarin, DOACs have fast onset of action and do not have fluctuating levels of anticoagulant effect except in patients with sudden deterioration of kidney and/or renal function, as well as in those receiving antibiotic therapy.
40
Despite these benefits, the exact role of DOACs in patients with ACS and AF is not fully elucidated. AF patients requiring oral anticoagulant therapy were systematically excluded from recent ACS trials testing DOACs, and patients with recent ACS were excluded from most phase III stroke prevention trials in AF patients. [41] [42] [43] [44] [45] So far, there have been no published head-to-head comparisons of any DOACs and warfarin in AF patients with ACS except for a subanalysis of the RE-LY study. 46 This substudy showed that dabigatran 110 mg BID was noninferior to warfarin in reducing stroke and systemic embolism and was associated with fewer major bleeds regardless of the use of DAP. However, the effect of dabigatran 150 mg BID on stroke and systemic embolism reduction was less prominent among patients using DAP. In addition, dabigatran 150 mg had similar rate of major bleeding to warfarin regardless of the use of DAP. In the time-dependent analysis, there was an additive effect on major bleeding risk with the number of antiplatelets used regardless of the oral anticoagulant dose used (HR, 1.60; 95% CI, 1.42-1.82 for a single vs. no antiplatelet and HR, 2.31; 95% CI, 1.79-2.98 for DAP vs. no antiplatelet). It is important to remember that this post hoc analysis was not part of the primary randomization and therefore must be interpreted as an observational (nonrandomized) finding. The use of DOACs in combination with aspirin and clopidogrel was more commonly studied in patients with ACS (but not AF). For instance, in the Re-DEEM study, the addition of different doses of dabigatran or placebo to DAP treatment post-ACS was assessed in 1,861 patients. 43 This phase II study showed that dabigatran was associated with a dose-dependent increase in bleeding events when compared with placebo for 50 mg (HR, The study aims to demonstrate noninferiority of dabigatran when compared with warfarin in efficacy and safety. However, it is important to note that both trials will not evaluate the combination of DOACs with DAP but will evaluate the efficacy and safety of dual therapy of DOAC combined with a single antiplatelet to TOAT with warfarin, aspirin, and clopidogrel.
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Switching Clopidogrel to a Novel Antiplatelet Agent
Although the previously discussed strategies were intended primarily to reduce the risk of bleeding associated with TOAT, switching clopidogrel to a novel antiplatelet agent aims to enhance the net clinical benefit rather than reducing the risk of bleeding. Novel antiplatelet drugs, such as prasugrel and ticagrelor, have been shown to be more effective at reducing recurrent MI, stroke, and death than clopidogrel in patients with ACS, but they were also associated with an increased risk of bleeding. 17, 18 The use of prasugrel in TOAT was studied by Sarafoff et al in 2013. 49 When compared with clopidogrel, the treatment with prasugrel in addition to aspirin and warfarin for a 6-month regimen was associated with a significant increase in the rate of bleeding (28.6 vs. 6.7%; HR, 3.2; 95% CI, 1.1-9.1; p ¼ 0.03). There was no significant difference in the combined ischemic secondary end points. Similarly, there was a recent report of two cases of fatal bleeding when prasugrel was used as part of TOAT. 50 To that end, use of prasugrel is generally not recommended as a part of a TOAT regimen. 19 Although ticagrelor was not studied to date in TOAT, it is likely to expose patients to a higher risk of bleeding as well given its results in ACS patients when compared with clopidogrel.
17
Guideline Recommendations
Both the American College of Cardiology/American Heart Association (AHA) and the European Society of Cardiology (ESC) recommend shortening the duration of TOAT as much as possible when indications dictate the use of all three antithrombotic agents. 19, 51 They then recommend the use of an oral anticogulant plus a single antiplatelet agent to reduce bleeding risk. The TOAT regimen recommended by the ESC is aspirin and clopidogrel combined with either warfarin or the lowest dose of DOAC (dabigatran 110 mg BID, rivaroxaban 15 mg daily, and apixaban 2.5 mg BID). The AHA, however, does not recommend the use of DOACs in TOAT since they were not evaluated in AF patients with ACS/PCI. The bleeding risk associated with prasugrel is excessive and was not tested for ticagrelor, hence both the AHA and the ESC recommend against the use of novel antiplatelets in TOAT. Both guidelines also recommend to maintain international normalized ratio levels between 2.0 and 2.5 in AF patients receiving warfarin along with DAP. 52 A summary of both guidelines' recommendations is provided in ►Table 3. 
Summary
TOAT (warfarin/aspirin/clopidogrel) increases the risk of bleeding when compared with the use of a combination of warfarin and a single antiplatelet agent. Dual therapy with warfarin and clopidogrel should be considered as an alternative to triple therapy in selected AF patients at low risk of stent thrombosis/recurrent cardiac events. If TOAT (warfarin/aspirin/clopidogrel) therapy is used, clinicians must weigh ischemic and bleeding risks of their patients when deciding on the duration of this combination due to the fact that its optimal duration is not established. The use of prasugrel in combination with warfarin and aspirin leads to a significant increase in bleeding compared with the combination of clopidogrel, aspirin, and warfarin. Therefore, the use of prasugrel (or ticagrelor) as a part of TOAT is not recommended.
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Among patients with ACS but no comorbid AF, the addition of a DOAC to antiplatelet therapy led to a modest reduction in cardiovascular events but on the expense of excessive bleeding risk. This was most evident in patients receiving DAP therapy. Notably, the reduction in ischemic events by DOACs was most promising when added to a single antiplatelet therapy. Therefore, studies evaluating the combination of DOACs and a single antiplatelet therapy in AF patients who experience an ACS were initiated and results are still pending.
